https://bmi1-receptor.com/inde....x.php/an-evaluation-
The overall survival rates of patients with previously extensively treated diffuse large B-cell lymphoma have been positively impacted by the introduction of chimeric antigen receptor (CAR) T-cell treatment. Still, the potentially life-threatening adverse effects associated with CAR T-cells and early relapses create a significant difficulty. Smaller monocentric analyses point to a possible immunomodulatory effect
Like
Comment
Share
